{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:08:48Z","timestamp":1789016928258,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The VEXAS syndrome, a genetically defined autoimmune disease, associated with various hematological neoplasms has been attracting growing attention since its initial description in 2020. While various therapeutic strategies have been explored in case studies, the optimal treatment strategy is still under investigation and allogeneic cell transplantation is considered the only curative treatment. Here, we describe 2 patients who achieved complete molecular remission of the underlying\n                    <jats:italic>UBA1<\/jats:italic>\n                    mutant clone outside the context of allogeneic HCT. Both patients received treatment with the hypomethylating agent azacitidine, and deep molecular remission triggered treatment de-escalation and even cessation with sustained molecular remission in one of them. Prospective studies are necessary to clarify which VEXAS patients will benefit most from hypomethylating therapy and to understand the variability in the response to different treatment strategies.\n                  <\/jats:p>","DOI":"10.1007\/s00277-023-05611-w","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:02:34Z","timestamp":1705035754000},"page":"993-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["VEXAS syndrome: complete molecular remission after hypomethylating therapy"],"prefix":"10.1007","volume":"103","author":[{"given":"Katja","family":"Sockel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ganster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Bill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Annabell","family":"Georgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Balaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"27","key":"5611_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 383(27):2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med."},{"issue":"4","key":"5611_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","volume":"329","author":"DB Beck","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V et al (2023) Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA 329(4):318\u2013324. https:\/\/doi.org\/10.1001\/jama.2022.24836","journal-title":"JAMA"},{"issue":"16","key":"5611_CR3","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203\u20133215. https:\/\/doi.org\/10.1182\/bloodadvances.2021004976","journal-title":"Blood Adv"},{"issue":"11","key":"5611_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","volume":"36","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Zhao LP, Chevret S et al (2022) A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia 36(11):2739\u20132742. https:\/\/doi.org\/10.1038\/s41375-022-01698-8","journal-title":"Leukemia"},{"issue":"4","key":"5611_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.17893","volume":"196","author":"T Comont","year":"2022","unstructured":"Comont T, Heiblig M, Rivi\u00e8re E et al (2022) Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol 196(4):969\u2013974. https:\/\/doi.org\/10.1111\/bjh.17893","journal-title":"Br J Haematol"},{"issue":"8","key":"5611_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MJ et al (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 140(8):927\u2013931. https:\/\/doi.org\/10.1182\/blood.2022016642","journal-title":"Blood."},{"issue":"11","key":"5611_CR7","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41409-022-01774-8","volume":"57","author":"C Gurnari","year":"2022","unstructured":"Gurnari C, McLornan DP (2022) Update on VEXAS and role of allogeneic bone marrow transplant: considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 57(11):1642\u20131648. https:\/\/doi.org\/10.1038\/s41409-022-01774-8","journal-title":"Bone Marrow Transplant"},{"key":"5611_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27169","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Pascale MR, Vitale A et al (2023) Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27169","journal-title":"Am J Hematol"},{"issue":"11","key":"5611_CR9","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1097\/HS9.0000000000000661","volume":"6","author":"S Stasik","year":"2022","unstructured":"Stasik S, Burkhard-Meier C, Kramer M et al (2022) Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Adv 6(11):3294\u20133303. https:\/\/doi.org\/10.1097\/HS9.0000000000000661","journal-title":"Blood Adv"},{"key":"5611_CR10","doi-asserted-by":"publisher","unstructured":"Raaijmakers MHGP, Hermans M, Aalbers A, Rijken M, Dalm VASH, van Daele P (2021) Azacytidine treatment for VEXAS syndrome. Hemasphere 5(12):e661. https:\/\/doi.org\/10.1097\/HS9.0000000000000661","DOI":"10.1097\/HS9.0000000000000661"},{"issue":"23","key":"5611_CR11","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/bloodadvances.2018022053","volume":"2","author":"C Wenk","year":"2018","unstructured":"Wenk C, Garz AK, Grath S et al (2018) Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Blood Adv. 2(23):3447\u20133461. https:\/\/doi.org\/10.1182\/bloodadvances.2018022053","journal-title":"Blood Adv."},{"issue":"4","key":"5611_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminhematol.2021.09.001","volume":"58","author":"M Heiblig","year":"2021","unstructured":"Heiblig M, Patel BA, Groarke EM, Bourbon E, Sujobert P (2021) Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol. 58(4):239\u2013246. https:\/\/doi.org\/10.1053\/j.seminhematol.2021.09.001","journal-title":"Semin Hematol."},{"key":"5611_CR13","doi-asserted-by":"publisher","unstructured":"Battipaglia G, Vincenzi A, Falconi G et al (2023) New scenarios in vacuoles, E1 enzyme, X linked, autoinflammatory, somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia. Curr Res Transl Med 71(2):103386. https:\/\/doi.org\/10.1016\/j.retram.2023.103386","DOI":"10.1016\/j.retram.2023.103386"},{"issue":"7","key":"5611_CR14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/diagnostics12071590","volume":"12","author":"M Templ\u00e9","year":"2022","unstructured":"Templ\u00e9 M, Kosmider O (2022) VEXAS syndrome: a novelty in MDS landscape. Diagnostics (Basel). 12(7):1590. https:\/\/doi.org\/10.3390\/diagnostics12071590","journal-title":"Diagnostics (Basel)."},{"issue":"3","key":"5611_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 186(3):564\u2013574. https:\/\/doi.org\/10.1111\/bjd.20805","journal-title":"Br J Dermatol."},{"issue":"12","key":"5611_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 129(12):1595\u20131606. https:\/\/doi.org\/10.1182\/blood-2016-09-696013","journal-title":"Blood."},{"issue":"6","key":"5611_CR17","doi-asserted-by":"publisher","first-page":"E152","DOI":"10.1002\/ajh.25089","volume":"93","author":"R Martin","year":"2018","unstructured":"Martin R, Acha P, Ganster C et al (2018) Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol. 93(6):E152\u2013E154. https:\/\/doi.org\/10.1002\/ajh.25089","journal-title":"Am J Hematol."},{"key":"5611_CR18","doi-asserted-by":"publisher","unstructured":"Gutierrez-Rodrigues F, Kusne Y, Fernandez J et al (2023) Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood 142(3):244\u2013259. https:\/\/doi.org\/10.1182\/blood.2022018774","DOI":"10.1182\/blood.2022018774"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05611-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:16:44Z","timestamp":1722471404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05611-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5611"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05611-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3734133\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"10 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were collected under written informed consent (according to the principles of the Helsinki Declaration) as part of the HMA-NGS study, which has been approved by the Institutional Ethics Committee of each participating center. Both patients gave their consent to publish their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"KS served on advisory boards and received lecture fees from BMS\/Celgene and Novartis. KSG received honoraria from BMS, Jazz Pharmaceuticals, and Abbvie. MA served on advisory boards for Novartis. MB served on advisory boards and received lecture fees from Jazz Pharmaceuticals and served on advisory boards from FarmaTrust. MB received travel compensation from DKMS. DH received research funding from BMS, Jazz Pharmaceuticals, and lecture fees from BMS\/Celgene, Jazz Pharmaceuticals, and Novartis; he served on advisory boards for BMS, Novartis, Jazz Pharmaceuticals, Gilead, Takeda, and Hexal. CT is co-owner and CEO of AgenDix GmbH. CT has received lecture fees and\/or participated in advisory boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, and Illumina. CT has received research funding from Novartis and Bayer. CG, JAG, EB, and MU declare no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}